Precigen (PGEN) to Release Earnings on Wednesday

Precigen (NASDAQ:PGEN) is anticipated to release its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Precigen to post earnings of ($0.03) per share and revenue of $20.8070 million for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.

Precigen (NASDAQ:PGEN) last announced its earnings results on Wednesday, March 25th. The biotechnology company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.09. The business had revenue of $4.57 million during the quarter, compared to analyst estimates of $8.29 million. Precigen had a negative net margin of 2,588.21% and a positive return on equity of 2,317.96%. On average, analysts expect Precigen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Precigen Stock Up 4.6%

Precigen stock opened at $4.33 on Wednesday. Precigen has a one year low of $1.23 and a one year high of $5.47. The stock has a fifty day moving average of $3.77 and a 200 day moving average of $4.06. The company has a debt-to-equity ratio of 4.46, a quick ratio of 2.83 and a current ratio of 3.09. The stock has a market cap of $1.54 billion, a PE ratio of -3.23 and a beta of 1.07.

Insiders Place Their Bets

In other Precigen news, Director Randal J. Kirk sold 4,772,781 shares of the company’s stock in a transaction that occurred on Monday, March 30th. The shares were sold at an average price of $3.30, for a total value of $15,750,177.30. Following the completion of the transaction, the director directly owned 302,213 shares in the company, valued at $997,302.90. This represents a 94.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 47.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of PGEN. Xponance LLC boosted its holdings in Precigen by 21.3% in the 4th quarter. Xponance LLC now owns 14,191 shares of the biotechnology company’s stock worth $59,000 after buying an additional 2,496 shares during the period. BNP Paribas Financial Markets increased its stake in Precigen by 6.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 51,796 shares of the biotechnology company’s stock worth $170,000 after buying an additional 2,993 shares in the last quarter. Intech Investment Management LLC raised its holdings in Precigen by 5.2% during the fourth quarter. Intech Investment Management LLC now owns 63,018 shares of the biotechnology company’s stock valued at $263,000 after acquiring an additional 3,137 shares during the period. HighTower Advisors LLC lifted its position in shares of Precigen by 4.2% in the fourth quarter. HighTower Advisors LLC now owns 104,560 shares of the biotechnology company’s stock valued at $437,000 after acquiring an additional 4,249 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Precigen by 10.3% in the fourth quarter. The Manufacturers Life Insurance Company now owns 56,006 shares of the biotechnology company’s stock valued at $234,000 after acquiring an additional 5,222 shares in the last quarter. Hedge funds and other institutional investors own 33.51% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on PGEN. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precigen in a research note on Tuesday, April 21st. HC Wainwright upped their target price on shares of Precigen from $9.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Zacks Research upgraded shares of Precigen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Wall Street Zen upgraded shares of Precigen from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Finally, Citizens Jmp upped their price objective on Precigen from $8.00 to $9.00 and gave the stock a “market outperform” rating in a research note on Thursday, March 26th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $9.50.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.